NPHLA Tracker · Clinical trials (ClinicalTrials.gov)
Clinical Trial Tracker: Metabolic & Aesthetic Medicine
Clinical trials followed in metabolic and aesthetic medicine — obesity and incretin therapies, neurotoxins, dermal fillers, regenerative treatments and hair restoration — with each study’s status, phase and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 187
- Changed in 7 days
- 0
- Latest record
- Jurisdiction
- International / multiple
Records
187 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| Tirzepatide for Obesity and Meth Use DisorderNCT06745128Conditions: Obesity; Methamphetamine Use Disorder. Interventions: Tirzepatide | Completed | Phase 2 | University of Texas Southwestern Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06745128 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722Conditions: Diabetes Mellitus, Type 2. Interventions: Retatrutide; Semaglutide | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06260722 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07794579 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)NCT03407079Conditions: Healthy Volunteers; Overweight. Interventions: Sucralose; Placebo | Recruiting | Phase 2 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03407079 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838Conditions: Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma. Interventions: Tirzepatide | Not yet recruiting | Phase 2 | UNC Lineberger Comprehensive Cancer Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07078838 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLOW: GLP-1s to Enhance Lasting Optimal WeightNCT06861439Conditions: Obesity. Interventions: Tirzepatide | Active, not recruiting | Phase 4 | Wake Forest University Health Sciences | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06861439 (opens in a new tab)Primary source | System checked NPHLA updated |
| Treatment for "Asymmetric Crying Facies"NCT07802639Conditions: Hemifacial Microsomia; Facial Nerve Paralysis. Interventions: Botulinium toxin type A injection | Recruiting | Not applicable | Xiaolei Jin | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07802639 (opens in a new tab)Primary source | System checked NPHLA updated |
| Deep Brain Stimulation Surgery for Focal Hand DystoniaNCT02911103Conditions: Dystonia; Focal Dystonia; Musician's Dystonia. Interventions: DBS surgery; Medtronic Activa Rechargeable System | Active, not recruiting | Phase 1 / Phase 2 | National Institute of Neurological Disorders and Stroke (NINDS) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT02911103 (opens in a new tab)Primary source | System checked NPHLA updated |
| Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 DiabetesNCT07835360Conditions: Obesity (Disorder); Type 2 Diabetes Mellitus | Recruiting | Phase not stated | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07835360 (opens in a new tab)Primary source | System checked NPHLA updated |
| Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyNCT06759701Conditions: Diabetes; Prostate Cancer. Interventions: Tirzepatide | Recruiting | Early phase 1 | M.D. Anderson Cancer Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06759701 (opens in a new tab)Primary source | System checked NPHLA updated |
| A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538Conditions: Obesity. Interventions: ARO-INHBE; Placebo; Tirzepatide | Recruiting | Phase 1 / Phase 2 | Arrowhead Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06700538 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)NCT07817875Conditions: Obesity. Interventions: Tirzepatide; Placebo | Not yet recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07817875 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightNCT07842640Conditions: Chronic Weight Management. Interventions: ASC35 Injection B, for subcutaneous use; ASC35 Placebo Injection B, for subcutaneous use; Tirzepatide | Recruiting | Phase 1 | Ascletis Pharma (China) Co., Limited | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07842640 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-7: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093Conditions: Obesity; Overweight; Chronic Low Back Pain (CLBP). Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07035093 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Conditions: Diabetes Mellitus, Type 2. Interventions: Orforglipron; Dulaglutide | Not yet recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07668336 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesNCT05248893Conditions: Glabellar Lines. Interventions: AGN-151586 | Completed | Phase 3 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05248893 (opens in a new tab)Primary source | System checked NPHLA updated |
| Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles TendinopathyNCT07483320Conditions: Achilles Injuries Tendon; Achilles Tendinopathy (AT); Achilles Tendinitis, Left Leg; Achilles Tendinitis, Right Leg; Achilles Tendon Pain;…. Interventions: Platelet Rich Plasma; Extracorporeal Shockwave Therapy; Sham PRP; Sham ESWT | Not yet recruiting | Not applicable | Spaulding Rehabilitation Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07483320 (opens in a new tab)Primary source | System checked NPHLA updated |
| ASSET: Autologous Fat Grafting for the Treatment of Chronic TendinopathyNCT07748793Conditions: Chronic Tendinopathy. Interventions: Adipose Stem/Stromal Cells for Enthesis/Tendon Therapy (ASSET) Injection | Recruiting | Not applicable | Weill Medical College of Cornell University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07748793 (opens in a new tab)Primary source | System checked NPHLA updated |
| COMMIT-CD: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099Conditions: Crohn's Disease; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06937099 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide for the Treatment of Cannabis Use DisorderNCT07265752Conditions: Cannabis Use Disorder. Interventions: Tirzepatide; Placebo | Not yet recruiting | Phase 2 | Brigham and Women's Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07265752 (opens in a new tab)Primary source | System checked NPHLA updated |
| COMMIT-UC: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086Conditions: Ulcerative Colitis; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06937086 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277Conditions: Obesity; Weight Gain. Interventions: Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06439277 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06383390 (opens in a new tab)Primary source | System checked NPHLA updated |
| ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06672549 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372Conditions: Chronic Kidney Disease; Type 2 Diabetes; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo | Completed | Phase 2 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06131372 (opens in a new tab)Primary source | System checked NPHLA updated |
| Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren SyndromeNCT07838454Conditions: Sjogren Syndrome; Xerostomia; Exosome. Interventions: exosomes derived from human umbilical cord mesenchymal stem cells; Mesenchymal Stem Cells (MSC); Placebo | Not yet recruiting | Phase 2 | Banu Erkal | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07838454 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNCT07803744Conditions: Diabetes Mellitus, Type 1; Overweight; Obesity. Interventions: Tirzepatide; Acetaminophen; Placebo | Recruiting | Phase 1 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07803744 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar LinesNCT06937944Conditions: Moderate to Severe Glabellar Lines. Interventions: Rcombinant botulinum toxin type A for injection（Eveotox); OnabotulinumtoxinA (Botox); Placebo | Recruiting | Phase 3 | JHM BioPharma (Tonghua) Co. , Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06937944 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of an Intraoperative Polynucleotide Injection on Scar Quality After ThyroidectomyNCT07791953Conditions: Postoperative Surgical Scar; Scar; Scar Formation; Neck Scar. Interventions: Polynucleotide (PN-HPT); Sterile 0.9% Sodium Chloride | Not yet recruiting | Not applicable | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07791953 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Interventions: Tirzepatide; Retatrutide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07165028 (opens in a new tab)Primary source | System checked NPHLA updated |
| RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884Conditions: Urinary Incontinence,Stress. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07202884 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593Conditions: Peripheral Arterial Disease. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07223593 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-RAM: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocr…. Interventions: Orforglipron | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07613307 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471Conditions: Osteoarthritis. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07153471 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07241390 (opens in a new tab)Primary source | System checked NPHLA updated |
| ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190Conditions: Overweight; Obesity. Interventions: Eloralintide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07392190 (opens in a new tab)Primary source | System checked NPHLA updated |
| MINOX: Treatment of Androgenetic Alopecia in Men for 24 WeeksNCT04721548Conditions: Alopecia. Interventions: Minoxidil Topical Foam; Placebo | Completed | Phase 3 | Eurofarma Laboratorios S.A. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04721548 (opens in a new tab)Primary source | System checked NPHLA updated |
| Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGANCT06393452Conditions: Androgenetic Alopecia. Interventions: PP405 0.05% Topical Gel; Topical Vehicle Gel | Completed | Phase 2 | Pelage Pharmaceuticals, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06393452 (opens in a new tab)Primary source | System checked NPHLA updated |
| Platelet-Rich Plasma for Peyronie's DiseaseNCT07117955Conditions: Peyronies Disease. Interventions: Autologous Platelet Rich Plasma; Saline solution | Recruiting | Not applicable | Herlev Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07117955 (opens in a new tab)Primary source | System checked NPHLA updated |
| Treatment of Peyronie's Disease With Platelet-Rich PlasmaNCT06789510Conditions: Peyronies Disease. Interventions: Autologous Platelet Rich Plasma; Saline solution | Completed | Not applicable | Herlev Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06789510 (opens in a new tab)Primary source | System checked NPHLA updated |
| INFLAM MOTION: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829Conditions: Knee Osteoarthritis; Synovitis of Knee. Interventions: 4P004; Placebo (NaCl 0.9%) | Active, not recruiting | Phase 2 | 4Moving Biotech | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07225829 (opens in a new tab)Primary source | System checked NPHLA updated |
| BioM: Biological Profiles of Neuropeptides, Neurotrophins and miRNA in MigraineNCT07832032Conditions: Migraine. Interventions: Rimegepant 75 MG | Not yet recruiting | Phase not stated | Nordlandssykehuset HF | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07832032 (opens in a new tab)Primary source | System checked NPHLA updated |
| ENIGI: A European Network for the Investigation of Gender IncongruenceNCT01072825Conditions: Physical and Psychological Evaluation of Hormonal Therapy in Transsexual Persons. Interventions: questionnaires; blood sampling; clinical evaluation; Dermatology evaluation; Bone evaluation | Recruiting | Phase not stated | University Hospital, Ghent | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT01072825 (opens in a new tab)Primary source | System checked NPHLA updated |
| Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRINCT05525845Conditions: Healthy. Interventions: Functional Magnetic Resonance Imaging (pCASL-MRI); Intragastric Balloon; Elemental Meal; Hedonic Meal | Active, not recruiting | Not applicable | Mayo Clinic | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05525845 (opens in a new tab)Primary source | System checked NPHLA updated |
| AWAKEN: Phase 2/3 Efficacy and Safety of PP405 in Adult MalesNCT07819435Conditions: Androgenetic Alopecia. Interventions: PP405 0.05% Topical Gel; Vehicle Topical Gel | Not yet recruiting | Phase 2 / Phase 3 | Pelage Pharmaceuticals, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07819435 (opens in a new tab)Primary source | System checked NPHLA updated |
| SERCABOT: Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy SyndromeNCT06807164Conditions: Post-Mastectomy Neuropathic Pain Syndrome. Interventions: Capsaicin 8% Patch; Serratus Plane Block; Botulinum Toxin A | Recruiting | Phase 2 | Centre Oscar Lambret | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06807164 (opens in a new tab)Primary source | System checked NPHLA updated |
| OMERIC: Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast CancerNCT04653740Conditions: Advanced Breast Cancer. Interventions: specimen sample collection | Active, not recruiting | Not applicable | Centre Oscar Lambret | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04653740 (opens in a new tab)Primary source | System checked NPHLA updated |
| Body Fat as Determinant of Female Gonadal DysfunctionNCT03841981Conditions: Polycystic Ovary Syndrome; Hypothalamic Amenorrhea. Interventions: Anthropometric and physical examination; Indirect calorimetry, accelerometer and seven-day dietary recall; Biochemical,… | Completed | Phase not stated | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03841981 (opens in a new tab)Primary source | System checked NPHLA updated |
| Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic AlopeciaNCT05888922Conditions: Androgenetic Alopecia; Female Pattern Baldness. Interventions: Minoxidil Tablets; Minoxidil Topical; Placebo oral tablet; Vehicle solution | Active, not recruiting | Phase 3 | Industrial Farmacéutica Cantabria, S.A. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05888922 (opens in a new tab)Primary source | System checked NPHLA updated |
| Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung CancerNCT01629498Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stag…. Interventions: Image Guided Radiation Therapy; Image Guided Radiation Therapy; Intensity-Modulated Radiation Therapy; Intensity-Modula… | Active, not recruiting | Phase 1 / Phase 2 | M.D. Anderson Cancer Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT01629498 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) for two broad searches — obesity and incretin therapies, and aesthetic and regenerative medicine (botulinum toxin, dermal fillers, polynucleotides, exosomes, platelet-rich plasma) — and for every topic with a trial query, on the schedule set in the Source Registry. Each study is stored with its registry fields as published. Changes in overall status and newly posted results are recorded with the date the pipeline detected them.
This tracker lists every tracked study whose last registry update falls within the past 365 days, newest first. Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch dated within the last 365 days.
What does it cover?
Studies on ClinicalTrials.gov — from the United States and other countries — that match the configured searches, from the date tracking began. Studies registered elsewhere, described with other terms, or not updated in the last year are not included.
What are its limitations?
Registry data is supplied by sponsors and may be incomplete or out of date. Inclusion reflects search terms, not clinical importance. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.